北美膀胱活动不足市场，按类型（药物治疗、手术方法、尿道辅助装置、干细胞和基因疗法）、给药途径（口服、肠胃外和其他）、最终用户（医院、诊所、学术和研究机构和其他）、分销渠道（医院药房、零售药房和其他）划分的行业趋势和预测至 2029 年
北美膀胱活动不足市场分析与洞察
北美膀胱功能低下市场受到多种因素的推动，例如神经源性膀胱感染发病率上升、研究资金增加、膀胱功能低下 (UAB) 新疗法的开发、产品线的推出以及研发投资的增加，这些因素都推动了市场增长。目前，发达国家和新兴国家的医疗保健支出都有所增加，这有望为制造商开发新的创新产品创造竞争优势。此外，医疗保健支出的激增和膀胱疾病患病率的上升也对市场产生了积极影响。
然而，高昂的治疗费用限制了患者接受高质量、有效的治疗方案。因此，高昂的治疗程序费用对整体治疗成本产生了负面影响。此外，目前用于治疗 UAB 的药物在有效性和安全性方面尚未得到临床证实，因此需要开发新的治疗药物。
由于市场参与者的增加和新型药物的出现，北美膀胱功能低下市场预计在预测期内将增长。与此同时，制造商正在开展研发活动，以向市场推出新产品。
然而，预计与研究和调查相关的高成本将抑制市场增长，从而进一步影响新产品的上市。
研发项目数量的增加以及为促进创新有效治疗的新发展而建立的公私合作伙伴关系的兴起进一步影响了市场。
北美活动性膀胱市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。各地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品是推动预测期内市场需求的主要驱动力。
北美膀胱功能低下市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，北美膀胱功能低下市场将以 5.3% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按类型（药物治疗、外科手术方法、尿道辅助装置、干细胞和基因疗法）、给药途径（口服、肠外和其他）、最终用户（医院、诊所、学术和研究机构和其他）、分销渠道（医院药房、零售药房和其他） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
Astellas Pharma Inc.、Aurobindo Pharma.、Boehringer Ingelheim International GmbH、Macleods Pharmaceuticals Ltd.、Orion Corporation、ONO PHARMACEUTICAL CO., LTD.、Novartis AG、Pfizer Inc.、Cipla Inc.、Dr. Reddy's Laboratories Ltd.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Ltd.、Almirall, SA、Vesiflo, Inc. 和 Alkem Labs. 等 |
市场定义
膀胱活动不足（UAB）是一种临床病症，由于排尿时逼尿肌（膀胱的肌肉）收缩减少而出现排尿障碍。其特征是立即有尿意，因此，该病症与膀胱过度活动症（OAB）不同。本发明提供了一种可用于预防或治疗 UAB 的药物组合物，其具有改善尿流率的效果、改善膀胱过度扩张的效果（减少膀胱容量的效果），因此可用于预防或治疗 UAB。
而且，这是一种与近年来备受关注的以尿急为特征的OAB不同的疾病状态。UAB的原因包括糖尿病和酒精中毒等自主神经病变、根治性子宫切除术和根治性直肠癌等盆腔手术、脊柱裂等脊髓疾病，还有椎间盘突出症。患有严重和轻微膀胱疾病相关问题的患者通常需要药物治疗，并且需要多种疗法循环，如果得不到充分缓解，则继续治疗，这也对医疗费用产生了影响。
北美膀胱活动不足市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下面将详细讨论所有这些内容：
驱动程序
- 神经系统疾病患病率不断上升
UAB 是一种常见的神经系统疾病，神经和肌肉无法很好地协同工作，导致排尿时间延长，有时伴有膀胱排空不完全的感觉。在这种情况下，逼尿肌的收缩活动能力不佳，其特征是尿流缓慢、排尿犹豫和排尿费力，有时伴有膀胱排空不完全的感觉，有时甚至伴有储尿症状。因此，膀胱无法排空或仅部分排空，这是由于膀胱肌肉无法正常排尿造成的。
因此，UAB 患者可能出现各种排尿症状，并可能伴有大量残留尿。由于病情加重而导致的尿潴留并发症和由于长期残留尿导致的尿路感染 (UTI) 很常见，并且已成为一个问题。此外，这是一种与近年来备受关注的以尿急为特征的 OAB 不同的疾病状态。因此，神经源性膀胱疾病的患病率不断上升预计将推动市场增长。这将导致对能够检测患者的治疗的需求增加，因此市场将有望实现丰厚的增长。
- 医疗支出上涨
仪器、人力、医疗管理（以防研究人员受到伤害）、保险、运输、伦理委员会费用、数据处理和其他消耗品，导致市场参与者承担大量成本。医疗保健支出包括所有医疗保健服务、检测设备、计划生育活动和指定用于健康的紧急援助。国家卫生账户根据在国际公认框架内收集的支出提供许多指标。决定任何国家医疗保健支出的因素是收入（人均 GDP）、技术进步和医疗实践差异以及卫生系统特征。
医疗保健支出的增加同时有助于医疗保健组织和政府机构增加对更年期药物的研究活动、即将进行的临床试验和研发活动。此外，由于新产品的生产和制造成本，市场参与者需要充足的资金和资源分配，因此，政府在这种情况下起到了帮助作用。不断增长的医疗保健支出也有利于进一步的经济发展和医疗保健行业的增长。此外，人口可支配收入的增加也是一个有利因素。因此，预计医疗保健支出的增加将在未来推动市场增长。
机会
- 糖尿病泌尿系统并发症增多
已知的 UAB 病因之一包括自主神经病变，例如糖尿病。此外，糖尿病与泌尿系统疾病的早期发病和严重程度增加有关，从而导致代价高昂且令人衰弱的泌尿系统并发症。这些泌尿系统并发症，包括膀胱功能障碍和尿路感染等，对糖尿病男性和女性的生活质量有着深远的影响。糖尿病和泌尿系统疾病是非常常见的健康问题，随着年龄的增长，患病率和发病率显著增加。糖尿病的泌尿系统并发症是直接影响。糖尿病是最突出的疾病，全球患病率很高。
糖尿病相关的膀胱并发症可能是由于逼尿肌平滑肌交替、神经功能障碍和尿路上皮功能障碍引起的。根据所涉及的神经，糖尿病神经病变的影响范围从腿部不适和麻木到消化系统、泌尿道、血管和核心并发症。糖尿病数据的增加将显著增加全球糖尿病泌尿系统并发症的风险。因此，需要为正确治疗糖尿病泌尿系统并发症推荐未来的研究和临床护理方向。还需要其他组织的支持，以覆盖欠发达地区，解决被忽视的并发症。因此，这意味着糖尿病泌尿系统并发症的增加有望成为市场增长的机会。
克制/挑战
- 研发成本高
研发是修改治疗不同类型患者的程序的先决条件。新产品的研发成本较高，需要深入的研究和临床研究。研发的各个临床阶段都需要巨额投资，这可能会影响市场增长。研究成本涉及研究的规划和执行，而研究需要充足的资金和资源分配，这可能会影响市场的新发展。产品成本在市场上起着重要作用。市场上有许多诊断选择，但由于成本高昂，大多数人往往避免进行诊断。诊断方法的灵敏度和特异性更高，测试成本也随之增加。
该程序的高成本是由于治疗的多个检查点以及使用高科技方式执行此类程序。由于治疗的研发成本过高，限制了提供高质量和有效的解决方案。因此，高成本对整体治疗成本产生负面影响。因此，它将限制未来中低收入国家对治疗的需求。这表明，与研究和调查相关的高成本预计将抑制市场增长，从而进一步影响新产品在市场上的推出。
COVID-19 疫情后对北美膀胱活动不足市场的影响
COVID-19 对市场增长产生了积极影响，因为该地区对产品的需求普遍增加。随着该地区各种膀胱疾病的患病率不断上升，人们的健康意识也越来越强。由于病情加重而导致的尿潴留并发症和由于长期残留尿液而导致的尿路感染很常见，这已成为一个问题。因此，COVID-19 对这个市场产生了积极影响。
最新动态
- 2020 年 6 月，Vesiflo, Inc. 宣布 inFlow 尿道假体纳入医保范围，这是一种经 FDA 批准的磁耦合尿道内瓣膜泵装置，可供成年女性使用 29 天，作为间歇性导尿的替代方案。这有助于产品业务的快速扩张，并实现市场商业化。
- 2020 年 4 月，安斯泰来制药欧洲有限公司完成了一项针对膀胱活动性功能低下患者的临床试验。目前，ASP8302 正在进行 2 期临床试验，以研究该药物对膀胱活动性功能低下患者的安全性和耐受性。
北美膀胱活动不足市场范围
北美膀胱功能低下市场根据类型、给药途径、最终用户和分销渠道分为四个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
类型
- 药物治疗
- 手术方法
- 尿道辅助装置
- 干细胞和基因疗法
根据类型，市场分为药物治疗、手术方法、尿道辅助装置以及干细胞和基因疗法。
给药途径
- 口服
- 肠外
- 其他的
根据给药途径，市场分为口服、肠外和其他。
最终用户
- 医院
- 诊所
- 学术及研究机构
- 其他的
根据最终用户，市场分为医院、诊所、学术和研究机构等。
分销渠道
- 医院药房
- 零售药店
- 其他的
根据分销渠道，市场分为医院药房、零售药房和其他。
北美膀胱活动不足市场区域分析/见解
对北美膀胱活动不足市场进行了分析，并按类型、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。
北美膀胱活动不足市场报告涵盖的国家包括美国、加拿大和墨西哥。
- 2022 年，北美膀胱功能低下症市场预计将增长，原因是尿失禁 (UI)、UAB 等膀胱问题发病率上升。此外，老年人口的增加也推动了市场增长，因为年龄增加了膀胱问题（例如膀胱控制问题）的风险。UI 和 UAB 的患病率也随着年龄的增长而上升，老年人口是人口中增长最快的群体。
由于美国拥有主要参与者且制造设施数量不断增加，预计美国将在该地区占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战，以及国内关税和贸易路线的影响。
竞争格局和北美膀胱活动不足市场份额分析
北美膀胱功能低下市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对北美膀胱功能低下市场的关注有关。
市场上的一些主要参与者包括：
- 安斯泰来制药公司
- 奥罗宾多制药公司
- 勃林格殷格翰国际有限公司
- 麦克劳德制药有限公司
- 猎户座公司
- 小野制药株式会社
- 诺华公司
- 辉瑞公司
- 西普拉公司
- 雷迪博士实验室有限公司
- 梯瓦制药工业有限公司
- 太阳制药工业有限公司
- 阿尔米拉尔, SA
- Vesiflo 公司
- Alkem 实验室。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与国家/地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 NORTH AMERICA UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 NORTH AMERICA UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 NORTH AMERICA UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 39 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 40 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 41 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 42 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 43 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 44 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 46 NORTH AMERICA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 48 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 49 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 51 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 52 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 53 U.S. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 55 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 56 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 U.S. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 62 U.S. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 U.S. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 64 U.S. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 U.S. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 U.S. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 67 U.S. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 68 U.S. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 69 CANADA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 71 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 73 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 74 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 75 CANADA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 CANADA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 CANADA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 CANADA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 CANADA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 82 CANADA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 83 CANADA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 84 CANADA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 85 MEXICO UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 88 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 89 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 90 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 91 MEXICO BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 92 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 94 MEXICO BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 MEXICO SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 96 MEXICO URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 MEXICO STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 MEXICO UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 99 MEXICO UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 100 MEXICO UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA UNDERACTIVE BLADDER MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE NORTH AMERICA UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA UNDERACTIVE BLADDER MARKET
FIGURE 14 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
